Standout Papers

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis 2022 2026 2023 2024894
  1. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis (2022)
    Steven R. Ytterberg, Deepak L. Bhatt et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 53 standout
Sub-graph 1 of 21

Citing Papers

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
Therapeutic advances in rheumatoid arthritis
2024 Standout

Works of R. Fleischmann being referenced

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
2022 Standout

Author Peers

Author Last Decade Papers Cites
R. Fleischmann 794 182 290 304 38 1.4k
Jose L. Rivas 805 201 298 284 26 1.3k
Kenneth Kwok 934 215 470 274 60 1.5k
Rebecca Germino 603 138 227 321 22 1.1k
Hubert van Hoogstraten 872 197 496 414 58 1.3k
R J McKendry 876 276 351 205 37 1.6k
Marcel D. Posthumus 656 145 211 338 30 1.4k
Šárka Forejtová 1001 190 401 399 32 1.4k
Sergio Schwartzman 927 123 391 538 54 1.4k
Andreas Brandt 343 119 183 223 50 1.7k
Wenhui Xie 507 95 121 296 90 1.3k

All Works

Loading papers...

Rankless by CCL
2026